Created at Source Raw Value Validated value
Sept. 1, 2022, 10 p.m. usa

[{"arm_notes": "nan", "treatment_id": null, "treatment_name": "STI-1558", "treatment_type": "Drug", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": null, "treatment_name": "STI-1558", "treatment_type": "Drug", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": null, "treatment_name": "STI-1558", "treatment_type": "Drug", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": null, "treatment_name": "STI-1558", "treatment_type": "Drug", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": null, "treatment_name": "STI-1558", "treatment_type": "Drug", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": null, "treatment_name": "STI-1558", "treatment_type": "Drug", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": null, "treatment_name": "STI-1558", "treatment_type": "Drug", "pharmacological_treatment": "Pharmacological treatment"}]

[{"arm_notes": "Participants will receive a single 300 mg dose of STI-1558 or placebo. Cohort 1 will dose 6 subjects to STI-1558 and 2 subjects to placebo.", "treatment_id": 2470, "treatment_name": "Sti-1558", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "Participants will receive a single 600 mg dose of STI-1558 or placebo. Cohort 2 will dose 6 subjects to STI-1558 and 2 subjects to placebo.", "treatment_id": 2470, "treatment_name": "Sti-1558", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "Participants will receive a single 1200 mg dose of STI-1558 or placebo. Cohort 3 will dose 6 subjects to STI-1558 and 2 subjects to placebo.", "treatment_id": 2470, "treatment_name": "Sti-1558", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "Participants will receive a single 2000 mg dose of STI-1558 or placebo. Cohort 4 will dose 6 subjects to STI-1558 and 2 subjects to placebo.", "treatment_id": 2470, "treatment_name": "Sti-1558", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "Participants will receive a 300 mg dose of STI-1558 or placebo q12h on Day1 to Day7 and once in the morning on Day8 for a total of 15 doses.\n\nCohort 1 will dose 6 subjects to STI-1558 and 2 subjects to placebo.", "treatment_id": 2470, "treatment_name": "Sti-1558", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "Participants will receive a 600 mg dose of STI-1558 or placebo q12h on Day1 to Day7 and once in the morning on Day8 for a total of 15 doses.\n\nCohort 2 will dose 16 subjects to STI-1558 and 8 subjects to placebo.", "treatment_id": 2470, "treatment_name": "Sti-1558", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "Participants will receive a 800 mg dose of STI-1558 or placebo q12h on Day1 to Day7 and once in the morning on Day8 for a total of 15 doses.\n\nCohort 3 will dose 16 subjects to STI-1558 and 8 subjects to placebo.", "treatment_id": 2470, "treatment_name": "Sti-1558", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}]